Dolutegravir based two-drug regimen in clinical routine

被引：0

作者：

Hoeller, Hannes ^{[1
]}

Jaeger, Hans ^{[1
]}

Jonsson-Oldenbuettel, Celia ^{[1
]}

Heldwein, Silke ^{[1
]}

Schabaz, Farhad ^{[1
]}

von Krosigk, Ariane ^{[1
]}

Wiese, Carmen ^{[1
]}

Wolf, Eva ^{[2
]}

Noe, Sebastian ^{[1
]}

机构：

[1] MVZ Munchen Goethepl, Munich, Germany

[2] MUC Res GmbH, Munich, Germany

来源：

INFECTION | 2021年 / 49卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

016

引用

页码：S11 / S11

页数：1

共 50 条

[31] Two-drug regimens
Cahn, P.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 10 - 10
[32] Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era
Cento, Valeria
Perno, Carlo Federico
DIAGNOSTICS, 2021, 11 (05)
[33] Systematic literature review of real-world experience with the two-drug regimen dolutegravir and lamivudine in people with HIV who would not have met inclusion criteria for the phase III clinical program
Slim, J.
Ward, D.
Schneider, S.
Kabra, M.
Verdier, G.
Jones, B.
Letang, E.
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 86 - 88
[34] Impact on inflammatory and atherogenesis biomarkers with the two-drug regimen dolutegravir plus lamivudine in treatment-experienced people with HIV-1: a systematic literature review
Llibre, Joseph
Cahn, Pedro E.
Lo, Janet
Barber, Tristan J.
Mussini, Christina
van Welzen, Berend J.
Hernandez, Beatriz
Donovan, Cynthia
Kisare, Michelle
Sithamparanathan, Myooran
van Wyk, Jean
HIV MEDICINE, 2022, 23 : 54 - 55
[35] A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients
Ciccullo, Arturo
Baldin, Gianmaria
Capetti, Amedeo
Rusconi, Stefano
Sterrantino, Gaetana
d'Ettorre, Gabriella
Colafigli, Manuela
Modica, Sara
Lagi, Filippo
Giacomelli, Andrea
Cossu, Maria Vittoria
Restelli, Sibilla
De Luca, Andrea
Di Giambenedetto, Simona
ANTIVIRAL THERAPY, 2019, 24 (01) : 63 - 67
[36] Experience of dolutegravir/lamivudine (DTG/3TC) and dolutegravir/rilpivirine (DTG/RPV) two-drug antiretroviral regimens in a London tertiary centre
Hart, J.
Youle, M.
Burns, F.
Barber, T.
HIV MEDICINE, 2019, 20 : 19 - 19
[37] Perspectives on the Barrier to Resistance for Dolutegravir plus Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
Boffito, Marta
Waters, Laura
Cahn, Pedro
Paredes, Roger
Koteff, Justin
Van Wyk, Jean
Vincent, Tia
Demarest, James
Adkison, Kimberly
Quercia, Romina
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2020, 36 (01) : 13 - 18
[38] . Lamivudine-based two-drug regimens with dolutegravir or protease inhibitor: Virological suppression in spite of previous therapy failure or renal dysfunction
Matsuda, Elaine Monteiro
Campos, Ivana Barros
de Oliveira, Isabela Penteriche
Colpas, Daniela Rodrigues
Lopez-Lopes, Giselle Ibete Silva
Chiavegato, Victor Oliveira
Brigido, Luis Fernando de Macedo
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2023, 27 (03):
[39] Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Schneider, Stefan
Blick, Gary
Burke, Christina
Ward, Douglas
Benson, Paul
Felizarta, Franco
Green, Dallas
Donovan, Cynthia
Harper, Gavin
Merrill, Deanna
Metzner, Aimee A.
Mycock, Katie
Wallis, Hannah
Patarroyo, Jimena
Brogan, Andrew P.
Oglesby, Alan
INFECTIOUS DISEASES AND THERAPY, 2024, 13 (04) : 891 - 906
[40] Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Stefan Schneider
Gary Blick
Christina Burke
Douglas Ward
Paul Benson
Franco Felizarta
Dallas Green
Cynthia Donovan
Gavin Harper
Deanna Merrill
Aimee A. Metzner
Katie Mycock
Hannah Wallis
Jimena Patarroyo
Andrew P. Brogan
Alan Oglesby
Infectious Diseases and Therapy, 2024, 13 : 891 - 906

← 1 2 3 4 5 →